Agendia Acquires Rights To The Discovery Of A Major Drug Resistance Mechanism In Breast Cancer

Agendia BV, world leader in the rapidly evolving field of molecular diagnostics, announced that it has acquired the rights to the discovery of a major mechanism of resistance to the frequently-used breast cancer drug Herceptin(R), which is published in the October 15 issue of the journal "Cancer Cell". The antibody drug Herceptin(R) targets the HER2 protein, which is hyper-active in about one in four breast cancers and the HER2 protein contributes to aggressive cancer behavior. Striking initial responses are observed in combination with chemotherapy in more than half of treated patients. However, the majority of responding patients eventually develop resistance to Herceptin-based therapies. The laboratory of Agendia's Chief Scientific Of...